Clinical Trials Arena September 5, 2025
Congruence anticipates filing the clinical trial application in the second half of this year.
Congruence Therapeutics has completed a $32m funding round, earmarked for propelling its genetic obesity drug, CGX-926, into a Phase Ib proof of concept study.
The funding has been supported by various current investors, including FSTQ, Amplitude Ventures, Lumira, BDC Capital’s Thrive Venture Fund, Investissement Quebec, OrbiMed, Silver Arc, Alexandria, and Driehaus.
Congruence noted that CGX-926 is the initial clinical candidate that addresses melanocortin 4 receptor-deficient (MC4R-d) genetic obesity.
The company has outlined plans to initiate a Phase I study involving healthy volunteers and subsequently, the Phase Ib efficacy cohort targeting individuals with MC4R-d, with the trials expected to commence in early 2026.
Congruence anticipates filing the...
Today's Sponsors
Today's Sponsor